In CRC, STM2457 combined with PD-1 antibody demonstrates a synergistic effect, characterized by enhanced suppression of tumor volume and increased CD4+ or CD8+ T cells infiltration [142]. This evidence concerns the gene CD8A and colorectal carcinoma.